Showing 1 - 10 of 12,983
Aktuell weisen die Krankenkassen und der Gesundheitsfonds Überschüsse von über 20 Mrd. Euro auf. Für Daniel Bahr, Bundesminister für Gesundheit, eröffnen diese Überschüsse – neben der Abschaffung der Praxisgebühr – Spielräume für Prämien. Die zentrale Herausforderung an eine...
Persistent link: https://www.econbiz.de/10010877382
The health economics literature contains two models of selection, one with endogenous plan characteristics to attract good risks and one with fixed plan characteristics; neither model contains a regulator. Medicare Advantage, a principal example of selection in the literature, is, however,...
Persistent link: https://www.econbiz.de/10011184330
This brief methods paper explains how to use the NSW Government Health Costs of Care Standards to estimate the cost of presentations to emergency departments (ED) in NSW. We begin with a discussion of the allocation of presentations according to visit type, triage category and mode of separation...
Persistent link: https://www.econbiz.de/10010905973
This paper studies the consequences of physician authority on pharmaceutical prescribing. Physicians engage in a costly process of "matching" patients to the drug which most suits their particular conditions and characteristics.
Persistent link: https://www.econbiz.de/10005487332
GOOD HEALTH IS A CRUCIAL PART OF WELL-BEING BUT SPENDING ON HEALTH CAN BE JUSTIFIED ON ECONOMIC GROUNDS. THE GOAL OF REDUCING POVERTY PROVIDES A DIFFERENT BUT EQUALLY POWERFUL CASE FOR HEALTH INVESTMENTS. HOWEVER, IF POLICYMAKERS ARE TO ACCELERATE THE SUBSTANTIAL HEALTH GAINS OF RECENT DECADES,...
Persistent link: https://www.econbiz.de/10005408428
Increasing costs of most healthcare systems result in (major) financing problems and thus are the focus of many empirical inquiries. Researchers have found that mismanagement is often a consequence of misplaced incentives. This paper tries to outline some cases in which the demand side of...
Persistent link: https://www.econbiz.de/10005464729
Most beneficiaries of Medicare's Part D prescription drug insurance choose among private drug plans to receive their coverage. This paper is the first to examine the relationship between the number of competing plan sponsors and the cost of Part D during the program's first five years. Over the...
Persistent link: https://www.econbiz.de/10011161574
By Andrew Stocking (CBO), James Baumgardner (CBO), Melinda Buntin (Vanderbilt University), and Anna Cook (CBO) The structure of the Medicare Part D prescription drug program generally encourages plan sponsors to submit low bids. However, rules in the program relating to low-income beneficiaries...
Persistent link: https://www.econbiz.de/10011161604
Persistent link: https://www.econbiz.de/10011167290
This is an effort at explaining the reasons and rationale behind the rising mortality rate (CDR) in the South Indian State – Andhra Pradesh. Although the state’s performance in socio-economic sphere seems to be not that impressive, its performance in demographic transition during the last...
Persistent link: https://www.econbiz.de/10011261013